Cargando...
An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial
BACKGROUND: The number of injections in the dose escalation of subcutaneous immunotherapy (SCIT) is small for some currently used hypoallergenic allergoids, but can still be inconvenient to patients and can impair compliance. The aim of this trial was to compare safety and tolerability of an acceler...
Guardado en:
| Publicado en: | Clin Transl Allergy |
|---|---|
| Autores principales: | , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4736162/ https://ncbi.nlm.nih.gov/pubmed/26839682 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13601-016-0093-z |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|